^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:Rixathon (rituximab biosimilar) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    Sandoz Press Release
    Title:

    Sandoz receives approval in Europe for Rixathon® (biosimilar rituximab) to treat blood cancers and immunological diseases

    Excerpt:
    Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, announced today that the European Commission (EC) has approved Rixathon® (biosimilar rituximab*) for use in Europe….Rixathon is approved for non-Hodgkin’s lymphoma (follicular lymphoma and diffuse large B-cell lymphoma) and chronic lymphocytic leukemia...
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Cancer Chemother Pharmacol
    Title:

    Rituximab biosimilar for the treatment of diffuse large B-cell lymphoma: a phase 3 randomized study in India

    Published date:
    04/24/2023
    Excerpt:
    A total of 153 newly diagnosed DLBCL patients were randomized to receive either biosimilar rituximab or reference rituximab….The ORR at the end of Cycle 6 was 82.14% in the biosimilar rituximab and 85.71% in the reference rituximab group….
    DOI:
    10.1007/s00280-023-04530-x